Curateq Biologics, a wholly owned subsidiary of Aurobindo Pharma, has allotted 4,125,055 Compulsory Convertible Preference Shares (CCPSs) of Rs.10/- each to Dr. Satakarni Makkapati on 20 March 2025. Each CCPS is convertible into a maximum of one equity share of Rs.10/- each and on conversion into Equity Shares Dr. Satakarni Makkapati will be holding 2% of Equity Share capital of Curateq and Curateq will then cease to be a wholly owned subsidiary of the Company and continue as a subsidiary of the Company.
Dr. Satakarni Makkapati is Chief Executive Officer of Curateq and a Director of Aurobindo Pharma.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app